Inspire Pharmaceuticals, Inc. - Publications & Presentations for 2005

Posters, Presentations & Publications
For Presentations and Posters in PDF Adobe Acrobat Reader is required. If you experience problems downloading the PDF, see Note in right margin, or we can send an 11x17 hard copy to you. Please e-mail info@inspirepharm.com with name, address, & telephone number.

2008 2007 2006 2005 2004 2003 2002 2001 2000 1996-1999

Johnson FL, Boyer J, Crean CS, Durham T, Krishnamoorthy R, Kellerman DJ. Phase 1 pharmacokinetic, pharmacodynamic, and safety evaluation of a novel rapidly reversible intravenous platelet P2Y12 ADP receptor antagonist, INS50589. J Thromb Haemost 2005; 3 (Suppl 1): P2206.

Bode AP, Crean CS, Sun YS, Nifong W, Cowlen M, Anderson S, Peterson W, Boyer JL. Effect of INS50589, a reversible ADP-receptor antagonist, on platelet function and blood loss in a canine model of cardiopulmonary bypass. Poster presented at the American Society of Hematology 47th Annual Meeting. 2005 December 10-13; Atlanta, Georgia, USA.

Evans R, Bogden ME, Tservistas M, Braun A, Seeman S, Keller M. Comparison of the rates of drug delivery and the relative efficiencies of emitted and respirable dose for two different nebulizers yielding qualitatively similar aerosols. Poster presented at the Drug Delivery to the Lungs 16 Meeting. 2005 December 7-9; Edinburgh, Scotland.

Kellerman DJ, Chia VW, Ice JC. Comprehensive review of the in vivo ocular tolerability and safety of ELESTAT^® (epinastine ophthalmic solution, 0.05%). Poster presented at the 2005 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. 2005 November 4-9; Anaheim, California, USA.

Evans R, Ellis Bogden M, Tservistas M, Seeman S, Keller M. Optimization of aerosol characteristics of the eFLOW^® electronic nebulizer for pulmonary delivery of a P2Y2 agonist. Poster presented at the 19th Annual North American Cystic Fibrosis Conference. 2005 October 20-23; Baltimore, Maryland, USA. Poster in PDF

Douglass JG, Patel RI, Cowlen MC, Yerxa BR, Shaver SR, Crean CS, Peterson WM, Watson PS, Bednarski K, Plourde R Jr., Mahanty S, Boyer JL. INS50589, a potent, selective, and reversible inhibitor of P2Y12-mediated platelet aggregation. PowerPoint presentation at the 230^th American Chemical Society National Meeting and Exposition. 2005 August 28 - September 1; Washington, DC, USA.

Johnson FL, Boyer JL, Crean CS, Durham T, Krishnamoorthy R, Watson PS, Kellerman DJ. Phase 1 pharmacokinetic, pharmacodynamic, and safety evaluation of a novel rapidly reversible intravenous platelet P2Y12 ADP receptor antagonist, INS50589. Poster presented at The International Society on Thrombosis & Haemostasis XXth Congress and 51st Annual SSC Meeting. 2005 August 6-12; Sydney, Australia.

Mathews D, Schaberg A, Kellerman D, LaVange L, Engels J, Shaffer C. INS37217 (denufosol tetrasodium) inhalation solution: Phase 1 & 2 clinical experience. Presentation and poster presented at the 28th European Cystic Fibrosis Conference. 2005 June 23-25; Crete, Greece. Poster in PDF

LaVange L,Engels J, Knowles M, Deterding R, Mathews D, Shaffer C. Safety and efficacy of INS37217 inhalation solution in patient subgroups: Results of a phase 2 multicentre trial. Presentation and poster presented at the 28th European Cystic Fibrosis Conference. 2005 June 23-25; Crete, Greece. Poster in PDF

LaVange LM, Durham TA, Koch GG. Randomization-based nonparametric methods for the analysis of multicentre trials. Stat Methods Med Res. 2005 Jun;14(3): 281-301.

Schaberg AE, Durham TA, Kuhn KL, Caspar RA, LaVange LM. An evaluation of worst symptom reporting in a dry eye clinical trial. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2005 Annual Meeting. 2005 May 1-5; Fort Lauderdale, Florida, USA.

Shaver SR, Rideout JL, Pendergast W, Douglass JG, Brown EG, Boyer JL, Patel RI, Redick CC, Jones AC, Picher M, Yerxa BR. Structure-activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors. Purinergic Signalling. 2005; 1:183-191.

Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: Results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol. 2005 Apr;39(4):339-348.

Cowlen M, Crean C, Krishnamoorthy R, Watson PS, Boyer JL, Peterson WM, Anderson SA. Pharmacology and tolerability of INS50589, a reversible P2Y12 receptor antagonist with anti-platelet aggregation activity, administered by continuous intravenous infusion in rats and dogs. Poster presentation at the Society of Toxicology 44th Annual Meeting. 2005 March 6-10; New Orleans, Louisiana, USA.

Page last updated: 20-Jun-2008

Click here to download Acrobat Reader

Note: If you are having problems opening any of the Posters or Presentations in PDF, please refresh your page to clear out the attempt and then, with your mouse hovering over the link to the PDF document, right click and choose Save Target As, choose a location on your hard drive to save the document and click save. Once the download is complete you will be given a choice to Open, Open Folder or Close. Click Open and the PDF should open immediately. If you continue to have problems, please conact info@inspirepharm.com.